R&D
Crystalys Raises $130M to Advance Its Gout Drug Through Late-Stage Trials
The Series B will fund Phase 2 and Phase 3 studies of dotinurad, a uric-acid-lowering therapy already approved in several Asian markets.
Tag
#dotinurad